Ginkgo Bioworks Holdings (DNA) Common Equity (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has reported Common Equity for 7 consecutive years, with $420.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 31.43% year-over-year to $420.3 million; the trailing twelve-month figure through Jun 2026 stood at $420.3 million (down 31.43% YoY), and the FY2025 full-year result was $508.6 million, down 28.97% from the prior year.
• Common Equity fell to $420.3 million in Q2 2026 per DNA's latest filing, from $443.2 million in the prior quarter.
• Across five years, Common Equity topped out at $1.7 billion in Q4 2022 and bottomed at $420.3 million in Q2 2026.
• Historically, Common Equity has averaged $1.0 billion across 5 years, with a median of $910.2 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Common Equity surged 341.91% in 2022, then slumped 44.59% in 2024.
• Over 5 years, Common Equity stood at $1.7 billion in 2022, then sank by 36.81% to $1.1 billion in 2023, then tumbled by 34.73% to $716.1 million in 2024, then slipped by 28.97% to $508.6 million in 2025, then dropped by 17.36% to $420.3 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $420.3 million, $443.2 million, and $508.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.